S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
UK train strikes and energy hikes add to a week of turmoil
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
NIH to fund unproven ALS drugs under patient-backed law
Russia blindfolds, detains Ukraine nuclear plant chief
NASDAQ:SLGC

SomaLogic - SLGC Stock Forecast, Price & News

$2.90
-0.07 (-2.36%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.90
$3.06
50-Day Range
$2.90
$5.15
52-Week Range
$2.85
$14.72
Volume
1.44 million shs
Average Volume
1.22 million shs
Market Capitalization
$532.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.20

SomaLogic MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
320.7% Upside
$12.20 Price Target
Short Interest
Healthy
9.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.27mentions of SomaLogic in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.50) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Business Services Sector

194th out of 336 stocks

Commercial Physical Research Industry

11th out of 16 stocks

SLGC stock logo

About SomaLogic (NASDAQ:SLGC) Stock

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive SLGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SomaLogic and its competitors with MarketBeat's FREE daily newsletter.

SLGC Stock News Headlines

Analyzing SomaLogic (SLGC) & The Competition
Head-To-Head Survey: SomaLogic (SLGC) vs. Its Rivals
SomaLogic Reports Second Quarter 2022 Financial Results
SomaLogic to Announce First Quarter 2022 Financial Results
See More Headlines
Receive SLGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SomaLogic and its competitors with MarketBeat's FREE daily newsletter.

SLGC Company Calendar

Today
10/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:SLGC
Fax
N/A
Employees
320
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.20
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+320.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-87,550,000.00
Net Margins
-114.46%
Pretax Margin
-114.46%

Debt

Sales & Book Value

Annual Sales
$81.63 million
Book Value
$3.37 per share

Miscellaneous

Free Float
159,788,000
Market Cap
$532.01 million
Optionable
Not Optionable
Beta
1.53

Key Executives

  • Dr. Roy Smythe M.D. (Age 60)
    CEO & Director
    Comp: $1.27M
  • Mr. Shaun M. Blakeman (Age 44)
    Chief Financial Officer
    Comp: $316.49k
  • Dr. Jason Cleveland Ph.D.
    Chief Technology Officer
  • Dr. Nebojsa Janjic Ph.D. (Age 61)
    Chief Science Officer
  • Dr. Stephen A. Williams BS (Age 62)
    MB, Ph.D., Chief Medical Officer
  • Mr. Todd Johnson
    Exec. VP of Diagnostics Bus. Unit
  • Mr. Adam Taich
    Exec. VP of Life Sciences Bus. Unit
  • Ms. Lauren Glaser
    Sr. VP of Investor Relations & Strategic Fin.
  • Mr. Byron D. Hewett (Age 66)
    Advisor













SLGC Stock - Frequently Asked Questions

Should I buy or sell SomaLogic stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SomaLogic in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLGC shares.
View SLGC analyst ratings
or view top-rated stocks.

What is SomaLogic's stock price forecast for 2022?

4 brokers have issued twelve-month price targets for SomaLogic's shares. Their SLGC share price forecasts range from $9.00 to $16.00. On average, they expect the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 320.7% from the stock's current price.
View analysts price targets for SLGC
or view top-rated stocks among Wall Street analysts.

How have SLGC shares performed in 2022?

SomaLogic's stock was trading at $11.64 at the beginning of the year. Since then, SLGC shares have decreased by 75.1% and is now trading at $2.90.
View the best growth stocks for 2022 here
.

What guidance has SomaLogic issued on next quarter's earnings?

SomaLogic issued an update on its FY 2022 earnings guidance on Monday, September, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $106.95 million.

What is SomaLogic's stock symbol?

SomaLogic trades on the NASDAQ under the ticker symbol "SLGC."

How do I buy shares of SomaLogic?

Shares of SLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SomaLogic's stock price today?

One share of SLGC stock can currently be purchased for approximately $2.90.

How much money does SomaLogic make?

SomaLogic (NASDAQ:SLGC) has a market capitalization of $532.01 million and generates $81.63 million in revenue each year. The company earns $-87,550,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does SomaLogic have?

The company employs 320 workers across the globe.

How can I contact SomaLogic?

SomaLogic's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is ii.cmlifesciencesspac.com. The company can be reached via phone at 303-625-9000 or via email at investors@somalogic.com.

This page (NASDAQ:SLGC) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.